Ongoing

3

262

Europe

Prednisolone (Tablet 1mg), Prednisolone (Soluble Tablet 5mg), Prednisolone (Oral Solution 10mg/ml), Human Normal Immunoglobulin (IVIg 100mg/ml), Aspirin (Dispersible Tablet 75mg), Aspirin (Tablets 300mg), Prednisolone (Tablet 5mg), Prednisolone (Tablet 10mg), Prednisolone (Tablet 2.5mg), Prednisolone (Tablet 20mg), Prednisolone (Tablet 25mg), Prednisolone (Tablet 30mg), Methylprednisolone (500mg), Methylprednisolone (1000mg), Human Normal Immunoglobulin (IVIg 50mg/ml), Aspirin (Tablet 75mg), Methylprednisolone (40mg), Methylprednisolone (125mg), Methylprednisolone (2g), B01AC06, Tablet, Soluble tablet, Oral solution, Solution for injection/infusion, Dispersible tablet, Powder and solvent for solution for injection/infusion, Powder for injection, Asaflow (80mg), Aspirine (100mg), Aspegic 100mg, Cardioaspirine (100mg), Solu-Medrol S.A.B. (40mg), Octagam (50 mg/ml) solution for infusion, Octagam 10% solution for infusion, Privigen 100 mg/ml solution for infusion, Iqymune (100mg/mL), Okrido 6mg/ml drank

MRC CTU at UCL, Medical Research Council Clinical Trials Unit at University College London, UNIVERSITY COLLEGE LONDON, MRC Clinical Trials Unit at University College London (UCL), Innovative Medicines Initiative 2 Joint Undertaking, Innovative Medicines Initiative 2, Innovative Medicine Initiative 2 Joint Undertaking

Kawasaki Disease, Kawasaki Disease, Diseases [C] - Cardiovascular Diseases [C14]